Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Radiation Dermatitis Market to Witness Astonishing Growth at a CAGR of 14.62% During the Study Period [2018-2030], Forecasts DelveInsight

The Radiation Dermatitis market has a promising outlook with emerging therapies such as Tempol, BMX-001, and others. Also, the market is rising steadily, accountable for increasing Radiation Dermatitis Incidence

DelveInsight Logo

News provided by

DelveInsight Business Research, LLP

May 19, 2021, 12:30 ET

Share this article

Share toX

Share this article

Share toX

LAS VEGAS, May 19, 2021 /PRNewswire/ -- DelveInsight's "Radiation Dermatitis Market" report provides a thorough comprehension of the Radiation Dermatitis, historical and forecasted epidemiology, and the Radiation Dermatitis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Radiation Dermatitis market report also proffers an analysis of the current Radiation Dermatitis treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. 

 Some of the imperative takeaways of the Radiation Dermatitis Market Research Report 

  • The Radiation Dermatitis market size shall increase in the 7MM; among these countries, the US accounted for 51.8% of the overall Radiation Dermatitis market size in 2020. 
  • Radiation Dermatitis Market to observe growth due to the factors such as a huge population presents a massive market to any new entrant. Advances in radiation delivery technology, such as intensity-modulated radiation therapy, can help reduce radiation-induced skin toxicity in certain tumour types, such as breast cancer. 
  • A few factors are responsible for hampering the market growth, such as radiation leads to decreased quality of life; despite technological advances in radiation delivery and growing interest in managing skin reactions, there is no standard in Radiation Dermatitis management. There are limited prospective randomised data on the use of pharmacologic or supportive care agents, topical or non-topical, to prevent and treat the indication. There has been a steady rise in alternatives for radiation therapy in the oncology space that will decrease the Radiation Dermatitis incidence. Several off-label treatment options are currently available in the Radiation Dermatitis market, which will capture a considerable market share and thus present tough competition to any new entrant. 
  • Current treatment goals focus on improving the patient's comfort and minimising further injury or enhancing wound healing. As the entire landscape is devoid of effective pharmaceutical options in preventing and managing Radiation Dermatitis, the emerging drugs will significantly impact the existing market. 
  • Several key pharmaceutical companies such as Adamis Pharmaceuticals, Matrix Biomed, BioMimetix JV, and others are developing novel products to drift the Radiation Dermatitis treatment scenario positively. 

For further information on Market Impact by Therapies, visit: Radiation Dermatitis Drug Market Analysis 

Radiation Dermatitis is a condition caused by radiotherapy delivered during cancer management. Radiation dermatitis usually begins to occur within 1–4 weeks of treatment and continues for the duration of radiation therapy. It may require 2–4 weeks to heal after completion of treatment. 

DelveInsight states the total Radiation Dermatitis incident population in the 7MM countries to be 3,012,048 cases in 2020. It was also observed that males and females are equally affected by the disease.

The Radiation Dermatitis Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

  • Radiotherapy Utilization
  • Incident cases of Radiation Dermatitis
  • Grade-specific cases of Radiation Dermatitis
  • Treated cases of Radiation Dermatitis

Get a complete epidemiological segmentation @ Radiation Dermatitis Epidemiological Analysis 

Radiation Dermatitis Treatment Market 

Radiation Dermatitis management has two major objectives: prophylaxis and treatment. Radiation Dermatitis prophylaxis includes topical agents such as Aloe vera, gentle soap, petroleum-based ointments, topical corticosteroids, sucralfate derivatives, and others. While treating Radiation Dermatitis, physicians mostly recommended bland emollients, biafine, calendula, vitamin E, dressing, silver sulfadiazine cream, topical corticosteroid, and others.

In scarce clinical situations, surgical intervention may be considered, but it can also potentially exacerbate fibrosis. The exceptional situation is the suspicion of tumour recurrence or second cancer formation, where the surgical approach is preferable over conservative methods or observation. In these patients, surgeons performed partial mastectomy and latissimus dorsi muscle reconstruction, obtaining a satisfactory reduction of symptoms.

Future research should be conducted more systematically and should strive for a more rigorous study design. These studies should incorporate current knowledge regarding Radiation Dermatitis' pathophysiology and include objective and universal outcome measures, and these measures should be validated and account for patient-reported outcomes.

Despite Radiation Dermatitis increasing incidence, a standard treatment does not exist for its prevention and management. Many of the currently utilised interventions are often based upon anecdotal evidence, poorly powered studies, or physician preferences. Furthermore, trials evaluating topical agents have failed to demonstrate effectiveness in preventing and managing radiation-induced skin injury. 

Radiation Dermatitis Emerging Therapies Along with Key Players

  • Tempol (APC-400): Adamis Pharmaceuticals/ Matrix Biomed
  • BMX-001: BioMimetix JV

And several others.

Scope of the Radiation Dermatitis Market Insight Report  

  • Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 
  • Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
  • Radiation Dermatitis Markets Segmentation: By Geographies and By Radiation Dermatitis Therapies (Historical and Forecasted, Current and Upcoming) 
  • Dominant Market Companies investigating its candidates for Radiation Dermatitis: Adamis Pharmaceuticals/ Matrix Biomed, BioMimetix JV, and several others. 
  • Analysis: Comparative and conjoint analysis of emerging therapies. 
  • Case Studies
  • KOL's Views
  • Analyst's View

Request for a Webex demo of the report @ Radiation Dermatitis Treatment Market Size

Table of Contents 

1

Radiation Dermatitis Key Insights

2

Radiation Dermatitis Report Introduction

3

Radiation Dermatitis Market Overview at a Glance

4

Executive Summary of Radiation Dermatitis 

5

Radiation Dermatitis  Disease Background and Overview

6

Radiation Dermatitis Epidemiology and Patient Population

6.1

The United States

6.2

EU5 Countries

6.2.1

Germany

6.2.2

France

6.2.3

Italy

6.2.4

Spain

6.2.5

United Kingdom

6.3

Japan

7

Organisations contributing towards Radiation Dermatitis

8

Radiation Dermatitis Patient Journey

9

Case Reports

10

Radiation Dermatitis Emerging Therapies 

10.1

Tempol (APC-400): Adamis Pharmaceuticals/ Matrix Biomed 

10.2

BMX-001: BioMimetix JV

11

7MM Radiation Dermatitis Market Analysis

11.1

The United States Radiation Dermatitis Market Size

11.2

EU-5 Radiation Dermatitis Market Size

11.2.1

Germany Market Size

11.2.2

France Market Size

11.2.3

Italy Market Size

11.2.4

Spain Market Size

11.2.5

United Kingdom Market Size

11.3

Japan Radiation Dermatitis Market Size

12

KOL Views

13

Radiation Dermatitis Market Drivers

14

Radiation Dermatitis Market Barriers

15

SWOT Analysis of Radiation Dermatitis

16

Radiation Dermatitis Unmet Needs

17

Market Access

18

Appendix

19

DelveInsight Capabilities

20

Disclaimer

21

About DelveInsight

Browse full report with detailed TOC with charts, figures, tables @ Radiation Dermatitis Market Share Report

View Related Reports

  • Radiation Dermatitis Epidemiology Insight

DelveInsight's Radiation Dermatitis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Radiation Dermatitis in 7MM. 

  • Gene Therapy For Ocular Rare Disease Market 

DelveInsight's 'Gene Therapy for Ocular Rare Disease -Market Insights, Competitive Landscape and Market Forecast - 2026' report delivers an in-depth understanding of the indication. 

  • Generalized Pustular Psoriasis Market 

DelveInsight's Generalized Pustular Psoriasis Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of the disease. 

  • Adenosine Deaminase-Severe Combined Immunodeficiency Market 

DelveInsight's Adenosine Deaminase-Severe Combined Immunodeficiency Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease. 

  • Age-Related Vision Dysfunction Market

DelveInsight's Age-Related Vision Dysfunction Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of the disease. 

  • Hepatorenal Syndrome Market 

DelveInsight's Hepatorenal Syndrome Market Insights, Epidemiology, and Market Forecast report delivers an in-depth understanding of the epidemiology report. 

  • Acute Bacterial Skin and Skin-Structure Infection Market 

Pharma Companies Foray into the ABSSSI Market to Develop Novel Antibiotics and Tackle Antibiotic Resistance.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach. 

Contact Us:
Shruti Thakur
[email protected]  
+1(919)321-6187
www.delveinsight.com 

SOURCE DelveInsight Business Research, LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight

Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Graves' Orbitopathy Market Insights report includes a comprehensive understanding of current treatment practices, Graves' orbitopathy...

CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight

CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight

DelveInsight's CXCR Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.